Promotores: B. van de Water; P. Hogendoorn; J. Bovée Co-Promotor: E.H.J. Danen

Researchers of the Leiden University Medical Centre (LUMC) and the Leiden Institute of Chemistry have made an important discovery about the commonly used anti-cancer drug doxorubicin. They have found a way to reduce its side effects without sacrificing the effectiveness of the medication. This is encouraging…

Large parts of the research described in this Thesis aims at the development of oligopeptide-masked toxins and their in situ immunoproteasome-mediated activation.

PhD candidate Dennis Wander searches for the best of both worlds. That is to say: a cancer drug that is effective and also has minimal side effects. To this end, he makes new molecules inspired by two existing medicines. And not without result: ‘We have created a new variant that is very promising.’…

Last year, chemists Dennis Wander and Hermen Overkleeft contributed to an important discovery about a widely used cancer drug. Their research has now been recognised as Finalist for the PNAS Cozzarelli Prize in the Biomedical Sciences class.

This thesis describes the synthesis and biological evaluation of TLR2/6, TLR4, TLR7/8 and TLR9 ligands, of which the activity can be conditionally controlled.

In this thesis, we will utilize embryonic zebrafish tumour models to understand the interaction between engrafted human cancer cells and macrophages from the host, test drug administration modalities and anti-cancer efficacies of newly-developed PDT and PACT compounds, and test a light-triggered liposomal…

More and more medicines are becoming available that target a tumour’s specific traits. The use of chemotherapy is continually undergoing improvement.

PhD defence